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ABSTRACT 
The SARS-CoV-2 pandemic has produced global health and economic adverse impacts. The main 
measures being taken to control the spread of SARS-CoV-2 and of the virus-associated diseases (COVID-
19) are conceptually those that were taken to control the spread of SARS-CoV in the previous 
coronavirus-driven pandemic of 2002-2003: good hygiene, facemasks, and quarantine (lockdown).  The 
difference is the larger scale of these measures for SARS-CoV-2.   
A degraded/dysfunctional immune system appears to be the main determinant of serious/fatal 
reaction to viral infection (for COVID-19, SARS, and influenza alike).  There are four major approaches 
being employed or considered presently to augment or strengthen the immune system, in order to 
reduce adverse effects of viral exposure.  The three approaches that are focused mainly on augmenting 
the immune system are based on the concept that pandemics can be controlled/prevented while 
maintaining the immune-degrading lifestyles followed by much of the global population.  The fourth 
approach is based on identifying and introducing measures aimed at strengthening the immune system 
intrinsically in order to minimize future pandemics. 
Specifically, the four measures are: 1) restricting exposure to virus; 2) providing reactive/tactical 
treatments to reduce viral load; 3) developing vaccines to prevent, or at least attenuate, the infection; 4) 
strengthening the immune system intrinsically, by a) identifying those factors that contribute to 
degrading the immune system, then eliminating/reducing them as comprehensively, thoroughly, and 
rapidly as possible, and b) replacing the eliminated factors with immune-strengthening factors.  
A previous monograph [1] focused mainly on strengthening the immune system intrinsically, 
and secondarily on vaccine-related issues.  It identified many hundreds of factors that contribute to 
weakening the immune system, as well as measures that can strengthen it.   
The present monograph focuses on vaccine safety.   A future COVID-19 vaccine appears to be 
the treatment of choice at the national/international level globally.  Vaccine development has been 
accelerated to achieve this goal in the relatively near-term, and questions have arisen whether vaccine 
safety has been/is being/will be compromised in pursuit of a shortened vaccine development time.   
In addition to identifying short-term adverse vaccine effects, the present monograph identifies 
potential mid-and long-term adverse vaccine effects that cannot be identified in short-term tests 
characteristic of vaccine efficacy testing. To ensure vaccine safety, long-term testing under real-life 
conditions (exposures to multiple toxic stimuli) is required.  There is an incompatibility between the 
accelerated vaccine development times being pursued by government and industry and the long times 
required for validation of vaccine safety. 
In summary, it is difficult to see how safe COVID-19 vaccines can be developed and fully tested 
for safety on development time scales of one or two years, as proposed presently.  The only real 
protection against a future COVID-19 pandemic or any other viral pandemic is the one that was 
demonstrated to work in the SARS, MERS, and COVID-19 pandemic, and in the annual influenza 
pandemics: a healthy immune system capable of neutralizing incoming viruses as nature intended. 
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Chapter 1 – Introduction 
1A. Background 
Over the past two decades, there have been at least three major coronavirus-based infectious 
disease outbreaks/epidemics/pandemics: Severe Acute Respiratory Syndrome (SARS), 2002-2003; 
Middle East Respiratory Syndrome (MERS), starting in 2012; COVID-19, starting in December 2019.  
There are a number of similarities among these three infectious diseases, including abnormal values of 
selected biomarkers (e.g., neutrophils, lymphocytes, albumin, CRP, TNF-alpha, etc.), pulmonary 
inflammation, pulmonary damage.  The most important similarity among these infectious diseases is the 
demographic affected most severely.  This demographic tends to be the elderly, with comorbidities and 
degraded/dysfunctional immune systems, and others with degraded/dysfunctional immune systems [2-
12].  While there is some decline in the immune system with age, comorbidity is a stronger predictor of 
impaired immunity than chronological age in older adults [13-14]. 
There are also similarities between COVID-19 and influenza: “Both (COVID-19 and influenza) 
cause fever, cough, body aches and fatigue; sometimes vomiting and diarrhea; can be mild or severe, 
even fatal in rare cases; can result in pneumonia” [15].  Additionally, “Neither virus is treatable with 
antibiotics, which only work on bacterial infections; both are treated by addressing symptoms, such as 
reducing fever; severe cases may require hospitalization and support such as mechanical ventilation” 
[15].  Both COVID-19 and influenza share the demographic affected most severely, as well. 
The main measures being taken to control the spread of the SARS-CoV-2 coronavirus (the virus 
mainly associated with COVID-19) are conceptually those that were taken to control the spread of the 
SARS-CoV coronavirus in 2002-2003: good hygiene and quarantine (lockdown).  The difference is the 
scale of these measures.  Currently, many countries are on lockdown (at different levels of severity), 
restricting many activities and businesses that involve gatherings of large numbers of people in close 
proximity.  As of mid-September, 2020, it is unknown how long these restrictions will be in place. 
1B. Treatments 
There are myriad efforts being pursued to develop treatments and preventative measures for 
COVID-19.  Some of these will now be outlined. 
If treatments are defined as a set of actions that improve health, then (at least) two types of 
treatments are possible.  The first type can be defined as positive treatments.  They can be sub-divided 
into high-tech treatments and low-tech treatments.  The high-tech are the classical treatments where 
drugs (or supplements) and/or radiation and/or surgery are implemented, and symptoms are alleviated.  
These high-tech positive treatments are basically a reactive tactical response to abnormal markers of 
health.  They can be applied for the short-term (e.g., antibiotics for bacterial infections, antivirals for 
viral infections, etc.), or for the long-term (e.g., statins, blood thinners, antihypertensives, etc.).  The 
low-tech treatments involve dietary, sleep, and other behavioral changes shown to impact the immune 
system positively (see section A4-C of our previous COVID-19 monograph [1] for a bibliography of low-
tech immune system strengthening factors).  For long-term benefit, these low-tech treatments need to 
be maintained indefinitely.  On average, the high-tech treatments have greater risk than the low-tech 
treatments. 
Vaccine Safety                                                    Copyright © 2020                                                        Kostoff et al 
 
6 
 
The second type can be defined as negative-negative treatments, where those factors that 
contribute to disease are first identified and then removed.  The name derives from the mathematics 
world, where a negative of a negative is a positive.  These negative-negative treatments are basically a 
proactive strategic response to abnormal markers of health, and typically involve long-term changes in 
lifestyle and harmful exposures for improved health.   
1B1. Tactical Treatments 
Much of the effort to help the most vulnerable COVID-19 demographic at this time has been 
searching for, and experimenting with, treatments that were/are used to combat other (mainly) viral 
diseases (aka repurposed treatments).  These treatments include, but are not limited to: 
Actemra/Tocilizumab; Avigan/Favipiravir; Azithromycin; Baricitinib/Olumiant; 
Bevacizumab/Avastin; Calquence/Acalabrutinib; Chloroquine; Colcrys/Colchicine; Convalescent Plasma; 
EIDD-2801; Fingolimod/Gilenya; Galidesivir; Hydroxychloroquine; Ilaris/Canakinumab; Ivermectin; 
Jakafi/Ruxolitinib; Kaletra/Lopinavir/Ritonavir; Kevzara/Sarilumab; Kineret/Anakinra; Leronlimab; 
Mavrilimumab; Methylprednisolone; Olumiant/Baricitinib; Otezla/Apremilast; Remdesivir; 
Tamiflu/Oseltamivir; Umifenovir/Arbidol; Xeljanz/Tofacitinib [16-18]. 
Other novel treatments could be identified using our Literature-Related Discovery and 
Innovation (LRDI)-based treatment repurposing methodology [19]. 
1B2. Strategic Treatments 
Strategic treatments were the focus of our previous COVID-19 monograph [1].  Their 
identification is a two-step process.  First, markers of immune system health (ranging from specific 
biomarkers to more general descriptors) are selected.  Second, those substances (e.g., smoking, excess 
alcohol, pesticides, etc.) behaviors (e.g., sedentary lifestyle, substance abuse, etc.), and other toxic 
stimuli that degrade the levels of these markers (i.e., lead to immune dysfunction, immunotoxicity, 
immunosuppression, etc.) are then identified and recommended for elimination.  The strategic 
treatments identified in the previous monograph are those contained within the immune system core 
literature.  Additional novel strategic treatments could also be identified using our LRDI-based treatment 
repurposing methodology [19]. 
1B3. Reactive Tactical vs Proactive Strategic Treatments 
The reactive tactical treatment approach for countering infections from viral exposure improves 
biomarker levels and reduces symptoms (if successful), but ordinarily does little to improve the body’s 
resistance to disease.  For viral infections, the tactical treatments will do little to strengthen the 
degraded/dysfunctional immune (and other) system.  After tactical treatments for one viral infection, 
people with degraded/dysfunctional immune systems will again be vulnerable to serious infectious 
consequences from exposure to the next harmful virus they encounter. 
The proactive strategic treatment approach will strengthen the immune (and other) system by 
removing those critical factors that contribute to disease and a degraded/dysfunctional immune system 
(unless irreversible damage has been done to the immune system, or individuals possess congenital or 
other hereditary damage to their immune system).  These strategic treatments tend to require long-
term adherence by their recipients.  In turn, these recipients of strategic treatments will be less 
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vulnerable to infection from exposure to the next pathogenic virus they encounter (SARS-CoV-2 or 
otherwise).  Like many healthy people who were exposed to SARS-CoV and SARS-CoV-2, these people 
who follow the (typically) long-term proactive strategic treatment regimen successfully may not even be 
aware they have been exposed to, or infected by, the coronavirus.  The only indication of their infection 
will be coronavirus antibodies in their serum. 
1C. Structure of Monograph 
The remainder of this monograph is structured as follows.  Chapter 2 overviews the 
methodology used to identify potential safety issues in successful COVID-19 vaccine development.  
Chapter 3 presents the potential safety issues that need to be addressed before a commercial vaccine 
can be viewed as intrinsically safe.  Chapter 4 contains the references for the present study.  Appendix 1 
provides a short bibliography of vaccine adverse effects. 
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Chapter 2 – Methodology 
 A hybrid methodology was used to identify references showing potential long-term adverse 
effects of vaccines and vaccine/infection-induced mechanisms that could contribute to these adverse 
effects.  Based on reading myriad vaccine adverse effects review articles, terms showing mechanisms 
were extracted (e.g., antibody-dependent enhancement, viral interference, route of infection, original 
antigenic sin, etc), and used as a Medline query to retrieve potentially relevant articles.  These articles 
were read, and the most relevant ones extracted.  Their titles were entered into the Web of Science, 
and the citation network was explored (citing papers, cited papers, papers that shared common 
references, etc).  Those records were read, and the most relevant ones extracted for this monograph.  
  
Vaccine Safety                                                    Copyright © 2020                                                        Kostoff et al 
 
9 
 
Chapter 3 – Results and Conclusions 
3A. Overview 
The main body of our previous COVID-19 monograph [1] addressed the first type of strategic 
treatment: 1) identification and removal of factors contributing to weakening the immune system (see 
section A4-A of the previous monograph [1] for a table of these contributing factors), and 2) 
identification and addition of factors contributing to strengthening  the immune system (see section A4-
C of the previous monograph [1] for a bibliography of low-tech immune system strengthening factors).  
The present chapter addresses the second type of strategic treatment: development and 
implementation of a COVID-19 vaccine.  The prospects for such a vaccine will be addressed from three 
criteria perspectives: development time, efficacy, and safety. 
Calina et al. evaluated the ongoing approaches to COVID-19 vaccine development, and stated: 
“Normally, the period of development of a vaccine is 12‑15 years” [20].  Against this backdrop, SARS-
CoV-2 vaccines are targeted for accelerated development, safety testing, manufacturing, and 
distribution by an order of magnitude [21-22].  Each of the accelerated steps listed in this reference has 
drastically reduced the time required from normal development. 
3B. Past Coronavirus Vaccine Development History 
There have been two prior coronavirus pandemics in the 21st century: SARS in 2002-2003, and 
MERS starting in 2012.  Vaccine development for each started/accelerated during the height of each 
pandemic.  What have been the results of these prior coronavirus vaccine development efforts? 
According to a comprehensive 2019 article on MERS vaccine development [23], “To date, there 
is no specific treatment proven effective against this viral disease. In addition, no vaccine has been 
licensed to prevent MERS-CoV infection thus far ... In general, the potential vaccine candidates can be 
classified into six types: viral vector-based vaccine, DNA vaccine, subunit vaccine, nanoparticle-based 
vaccine, inactivated-whole virus vaccine and live-attenuated vaccine” 
According to a comprehensive 2020 article on SARS and MERS vaccine development [24], “As of 
April 2020, no vaccine is commercially available for these coronavirus strains”.  The rationale for lack of 
a vaccine is given by the following: “Reasons for the lack of commercial and effective vaccines for SARS 
and MERS are varied. In the case of MERS, it is likely that the vaccine development was delayed because 
of the scarcity of suitable and cost-effective small animal models during pre-clinical experimentation. In 
addition, it is probable that a vaccine has not been delivered because of the low interest in investing in a 
vaccine for a disease that has produced relatively low and geographically centralized cases (compared 
with other more global and persistent infectious diseases such as influenza, HIV and tuberculosis). This 
last factor might have also contributed to the lack of a vaccine for SARS, in the sense that it was 
considered pointless to continue investing in a vaccine for a disease whose cases ceased to be reported 
in 2004.” 
While interest in a vaccine may have waned after the SARS pandemic seemed to have 
terminated, research on such a vaccine persisted.  References in the above article showed SARS vaccine 
research continued for a decade or more after the pandemic had ended [25-26]. 
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Based on the experiences with SARS and MERS, successful vaccine development was not 
achieved after about a decade of research, or even more.  That does not bode well for COVID-19 
coronavirus vaccine development/safety testing/distribution for the one-year timescales being 
projected. 
3C. Challenges for Successful Vaccine Development 
3C1. Overview 
The main challenges facing successful coronavirus vaccine development can be summarized as 
time to development, efficacy of the vaccine and, most importantly, safety of the vaccine.  A 
complementary perspective on some of the problems listed in [20] can be stated as follows: 
“First, although the virus’s spike protein is a promising immunogen for protection, optimizing 
antigen design is critical to ensure optimal immune response. Debate continues over the best approach 
— for example, targeting the full-length protein or only the receptor-binding domain. 
Second, preclinical experience with vaccine candidates for SARS and the Middle East respiratory 
syndrome (MERS) have raised concerns about exacerbating lung disease, either directly or as a result of 
antibody-dependent enhancement. Such an adverse effect may be associated with a type 2 helper T-cell 
(Th2) response. Hence, testing in a suitable animal model and rigorous safety monitoring in clinical trials 
will be critical” [27]. 
Numerous mid- and longer-term potential adverse effects from vaccines have been identified.  
Their themes are summarized initially, followed by excerpts from specific cited references 
1) Antibody-Dependent Enhancement (where enhanced virus entry and replication in a number of cell 
types is enabled by antibodies);  
-1a) Intrinsic Antibody-Dependent Enhancement (where nonneutralizing antibodies raised by natural 
infection with one virus may enhance infection with a different virus) 
-1b) Immune Enhancement (enhancement of secondary infections via immune interactions) 
-1c) Cross-reactivity (an antibody raised against one specific antigen has a competing high affinity 
toward a different antigen.) 
-1d) Cross-Infection Enhancement (infection enhancement of one virus by antibodies from another 
virus) 
2) Vaccine-associated Virus Interference (where vaccinated individuals may be at increased risk for other 
respiratory viruses because they do not receive the non-specific immunity associated with natural 
infection);  
3) Vaccine-Associated Imprinting Reduction (where vaccinations could also reduce the benefits of 
‘imprinting’, a protection conferred upon children who experienced infection at an early age);  
4) Non-Specific Vaccine Effects on Immune System (where previous infections can alter an individual's 
susceptibility to unrelated diseases);  
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5) Impact of Infection Route on Immune System (where immune protection can be influenced by the 
route of exposure/delivery);  
6) Impact of Combinations of Toxic Stimuli (where people are exposed over their lifetime to myriad toxic 
stimuli that may impact the influence of any vaccine); 
7) Antigenic Distance Hypothesis (negative interference from prior season’s influenza vaccine (v1) on the 
current season’s vaccine (v2) protection may occur when the antigenic distance is small between v1 and 
v2 (v1 ≈ v2) but large between v1 and the current epidemic (e) strain (v1 ≠ e).) 
8) Bystander Activation (activation of T cells specific for an antigen X during an immune response against 
antigen Y) 
9) Gut Microbiota (Impact of gut microbial composition on vaccine response) 
10) Homologous Challenge Infection Enhancement (the strain of challenge virus used in the testing assay 
is very closely related to the seed virus strain used to produce the vaccine that a subject received)  
11) Immune Evasion (evasion of host response to viral infection) 
12) Immune Interference (interference from circulating antibody to the vaccine virus) 
-12a) Original antigenic sin (propensity of the body's immune system to preferentially utilize 
immunological memory based on a previous infection when a second slightly different version of that 
foreign entity (e.g. a virus or bacterium) is encountered.) 
13) Prior Influenza Infection (effects of prior influenza infection on severity of future disease symptoms) 
14) Timing between Viral Exposures (elapsed time between viral exposures) 
15) Vaccine-Associated Enhanced Respiratory Disease (where vaccination enhances respiratory disease) 
16) Chronic Immune Activation (continuous innate immune responses) 
   Each of these effects will now be addressed in more detail. 
3C2.  Potential Mechanistic Adverse Effects from Vaccines 
3c2a. Antibody-Dependent Enhancement (where enhanced virus entry and replication in a number of 
cell types is enabled by antibodies) 
“preclinical experience with vaccine candidates for SARS and the Middle East respiratory 
syndrome (MERS) have raised concerns about exacerbating lung disease, either directly or as a result of 
antibody-dependent enhancement. Such an adverse effect may be associated with a type 2 helper T-cell 
(Th2) response. Hence, testing in a suitable animal model and rigorous safety monitoring in clinical trials 
will be critical” [27]. 
“Examples of vaccine-induced enhancement of susceptibility to virus infection or of aberrant 
viral pathogenesis have been documented for infections by members of different virus families. Several 
mechanisms, many of which still are poorly understood, are at the basis of this phenomenon … Certain 
experimental lentiviral vaccines even proved to be counterproductive: they rendered vaccinated 
subjects more susceptible to infection rather than protecting them. For vaccine-induced enhanced 
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susceptibility to infection with certain viruses like feline coronavirus, Dengue virus, and feline 
immunodeficiency virus, it has been shown that antibody-dependent enhancement (ADE) plays an 
important role … Consequently, vaccine-induced enhancement has been a major stumble block in the 
development of certain flavi-, corona-, paramyxo-, and lentivirus vaccines. Also recent failures in the 
development of a vaccine against HIV may at least in part be attributed to induction of enhanced 
susceptibility to infection” [28]. 
“for a number of viral pathogens, under certain conditions, antibodies provide an attractive 
means of enhanced virus entry and replication in a number of cell types. Known as antibody-dependent 
enhancement (ADE) of infection, the phenomenon occurs when virus-antibody immunocomplexes 
interact with cells bearing complement or Fc receptors, promoting internalization of the virus and 
increasing infection. Frequently associated with exacerbation of viral disease, ADE of infection presents 
a major obstacle to the prevention of viral disease by vaccination and is thought to be partly responsible 
for the adverse effects of novel antiviral therapeutics such as intravenous immunoglobulins.” [29]. 
“Previous studies have shown that the immunization of mice with inactivated whole SARS- CoV, 
the immunization of rhesus macaques with MVA- encoded S protein and the immunization of mice with 
DNA vaccine encoding full- length S protein could induce ADE or eosinophil- mediated mmunopathology 
to some extent, possibly owing to low quality and quantity of antibody production. Additionally, we 
need to consider whether a vaccine is safe and effective in aged hosts. 
For instance, double- inactivated SARS-CoV vaccine failed to induce neutralizing antibody 
responses in aged mice. Furthermore, although an alum- adjuvanted double- inactivated SARS- CoV 
vaccine elicited higher antibody titres in aged mice, it skewed the IgG subclass toward IgG1 instead of 
IgG2, which was associated with a T helper 2 (TH2)- type immune response, enhanced eosinophilia and 
lung pathology.” [30].  Also, see [31-33]. 
“Under certain circumstances, a viral infection or vaccination may result in a subverted immune 
system, which may lead to an exacerbated illness. Clinical evidence of enhanced illness by preexisting 
antibodies from vaccination, infection or maternal passive immunity is available for several viruses and 
is presumptively proposed for other viruses…..It has been confirmed that certain infection- and/or 
vaccine-induced immunity could exacerbate viral infectivity in Fc receptor- or complement bearing cells- 
mediated mechanisms.” [34]. 
3C2a1. Intrinsic Antibody-Dependent Enhancement (where nonneutralizing antibodies raised by natural 
infection with one virus may enhance infection with a different virus) 
“Preexisting antibodies may enhance viral infections. In dengue, nonneutralizing antibodies 
raised by natural infection with one of four dengue viruses (DENVs) may enhance infection with a 
different virus by a process we term "intrinsic antibody-dependent enhancement" (iADE). In addition, 
nonprotective antibodies raised by formalin-inactivated respiratory syncytial virus (RSV) and measles 
virus vaccines have led to enhanced disease during breakthrough infections. Infections under iADE 
conditions not only facilitate the process of viral entry into monocytes and macrophages but also modify 
innate and adaptive intracellular antiviral mechanisms, suppressing type 1 interferon (IFN) production 
and resulting in enhanced DENV replication.” [35]. 
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“Using an adjuvanted and an unadjuvanted double-inactivated SARS-CoV (DIV) vaccine, we 
demonstrate an eosinophilic immunopathology in aged mice comparable to that seen in mice 
immunized with the SARS nucleocapsid protein, and poor protection against a nonlethal heterologous 
challenge…..In the absence of alum, DIV vaccine performed poorly in young animals challenged with 
lethal homologous or heterologous strains. In contrast, DIV vaccines (both adjuvanted and 
unadjuvanted) performed poorly in aged-animal models. Importantly, aged animals displayed increased 
eosinophilic immune pathology in the lungs and were not protected against significant virus replication. 
These data raise significant concerns regarding DIV vaccine safety and highlight the need for additional 
studies of the molecular mechanisms governing DIV-induced eosinophilia and vaccine failure, especially 
in the more vulnerable aged-animal models of human disease.” [36]. 
“Dengue provides the most abundant example in human medicine and the greatest human 
illness burden caused by the phenomenon of intrinsic antibody-dependent infection enhancement 
(iADE). In this immunopathological phenomenon infection of monocytes or macrophages using 
infectious immune complexes suppresses innate antiviral systems, permitting logarithmic intracellular 
growth of dengue virus. The four dengue viruses evolved from a common ancestor yet retain similar 
ecology and pathogenicity, but although infection with one virus provides short-term cross-protection 
against infection with a different type, millions of secondary dengue infections occur worldwide each 
year. When individuals are infected in the virtual absence of cross-protective dengue antibodies, the 
dengue vascular permeability syndrome (DVPS) may ensue.” [37]. 
“These symptoms are the result of uncontrolled immune activation. Macrophages and dendritic 
cells are the main target of dengue virus (DENV) and the cellular source of cytokines associated with this 
immune activation. Macrophages and dendritic cells express several innate immune receptors that have 
been implicated in DENV immune activation, of which, CLEC5A, RIG-I and MDA5 are most important. 
Notably, activation of these receptors have profound effects on adaptive immune responses against 
DENV. This review will focus on how innate immune receptors drive DENV immune activation by 
inducing inflammatory cytokines and by activating adaptive immune responses.” [38]. 
“Antibody-dependent enhancement (ADE) of dengue virus infection has been proposed as the 
early mechanism underlying DHF/DSS. Dengue cross-reactive antibodies raised following a first dengue 
infection combine with a second infecting virus to form infectious immune complexes that enter Fc-
receptor-bearing cells. This results in an increased number of infected cells and increased viral output 
per cell. At the late illness stage, high levels of cytokines, possibly the result of T cell elimination of 
infected cells, result in vascular permeability, leading to shock and death.” [39]. 
“Epidemiologic and observational studies demonstrate that the majority of severe dengue cases, 
dengue hemorrhagic fever and dengue shock syndrome (DHF/DSS), occurs predominantly in either 
individuals with cross-reactive immunity following a secondary heterologous infection or in infants with 
primary DENV infections born from dengue-immune mothers, suggesting that B-cell-mediated and 
antibody responses impact on disease evolution. We demonstrate here that B cells play a pivotal role in 
host responses against primary DENV infection in mice…..In addition, we show that poly and monoclonal 
anti-DENV-specific antibodies can sufficiently increase viral replication through a suppression of early 
innate antiviral responses and enhance disease manifestation, so that a mostly non-lethal illness 
becomes a fatal disease resembling human DHF/DSS. Finally, treatment with intravenous 
immunoglobulin containing anti-DENV antibodies confirmed the potential enhancing capacity of 
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subneutralizing antibodies to mediate virus infection and replication and induce severe disease 
manifestation of DENV-infected mice. Thus, our results show that humoral responses unleashed during 
DENV infections can exert protective or pathological outcomes and provide insight into the 
pathogenesis of this important human pathogen.” [40]. 
“2. Antibody-mediated enhancement of SARS-CoV infection with anti-SARS-CoV Spike immune-
serum was observed in vitro. 3. Antibody-mediated infection of SARS-CoV triggers entry into human 
haematopoietic cells via an FcgammaR-dependent and ACE2-, pH-, cysteine-protease-independent 
pathways. 4. The antibody-mediated enhancement phenomenon is not a mandatory component of the 
humoral immune response elicited by SARS vaccines, as pure neutralising antibody only could be 
obtained. 5. Occurrence of immune-mediated enhancement of SARS-CoV infection raises safety 
concerns regarding the use of SARS-CoV vaccine in humans and enables new ways to investigate SARS 
pathogenesis (tropism and immune response deregulation).” [41]. 
3C2a2. Immune Enhancement (enhancement of secondary infections via immune interactions) 
“To determine whether this strategy could be transposed to another animal model, and by 
extension, to humans, we have evaluated the efficacy of adenoviral vectors in a natural model of AIDS, 
infection of the cat by the feline immunodeficiency virus (FIV)…..Six weeks after the second 
administration, cats were challenged by the intraperitoneal route with the homologous strain, and viral 
burden in plasma was followed by quantitative RT-PCR. Immunisation with FIV antigens did not afford 
protection. Rather, viral RNA was detected at earlier time points in cats immunised against Gag than in 
cats immunised with a vector expressing an irrelevant antigen. Such immune-mediated enhancement 
did not appear to have a long-range impact on viral set point or inversion of the CD4(+)/CD8(+) ratio. 
Thus, in the feline AIDS model pre-existing immunity against a viral antigen exacerbated acute phase 
infection.” [42]. 
“The dengue viruses exist as four antigenically distinct serotypes. These four serotypes co-
circulate and interact with each other through multiple immune-mediated mechanisms. Though the 
majority of previous efforts to understand the transmission dynamics of dengue have assumed identical 
characteristics for these four serotypes, empirical data suggests that they differ from one another in 
important ways. Here, we examine dynamics and persistence in models that do not assume symmetry 
between the dengue viruses. We find that for serotype transmission rates that are only slightly 
asymmetric, increased transmissibility of secondary infections through immune enhancement increases 
the persistence of all dengue viruses in opposition to findings in symmetric models. We identify an 
optimal magnitude of immune enhancement that maximizes the probability of persistence of all four 
serotypes. In contrast to other pathogen systems where heterogeneity between serotypes in 
transmissibility facilitates competitive exclusion…..here we find that in the presence of Antibody 
Dependent Enhancement (ADE) heterogeneity can increase the persistence of multiple serotypes of 
dengue.” [43]. 
“Increasing evidence points to host Th17 inflammatory responses as contributing to the severe 
lung pathology and mortality of lower respiratory tract infections from coronaviruses. This includes host 
inflammatory and cytokine responses to COVID-19 caused by the SARS-2 coronavirus (SARS CoV2). From 
studies conducted in laboratory animals, there are additional concerns about immune enhancement and 
the role of potential host immunopathology resulting from experimental human COVID-19 vaccines. 
Here we summarize evidence suggesting there may be partial overlap between the underlying 
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immunopathologic processes linked to both coronavirus infection and vaccination, and a role for Th17 in 
immune enhancement and eosinophilic pulmonary immunopathology. Such findings help explain the 
link between viral-vectored coronavirus vaccines and immune enhancement and its reduction through 
alum adjuvants. Additional research may also clarify links between COVID-19 pulmonary 
immunopathology and heart disease.” [44]. 
“Here, an African green monkey (AGM) model was used to elucidate immune mechanisms that 
facilitate viral clearance but may also contribute to persistent lung inflammation following SARS-CoV 
infection. During primary infection, SARS-CoV replicated in the AGM lung for up to 10 days. Interestingly, 
lung inflammation was more prevalent following viral clearance, as leukocyte numbers peaked at 14 
days postinfection (dpi) and remained elevated at 28 dpi compared to those of mock-infected controls. 
Lung macrophages but not dendritic cells were rapidly activated, and both cell types had high activation 
marker expression at late infection time points…..In SARS-CoV homologous rechallenge studies, 11 of 
the 12 animals were free of replicating virus at day 5 after rechallenge. However, incidence and severity 
of lung inflammation was not reduced despite the limited viral replication upon rechallenge. Evaluating 
the role of antibodies in immune protection or potentiation revealed a progressive increase in anti-
SARS-CoV antibodies in lung and serum that did not correlate temporally or spatially with enhanced viral 
replication. This study represents one of the first comprehensive analyses of lung immunity, including 
changes in leukocyte populations, lung-specific cytokines, and antibody responses following SARS-CoV 
rechallenge in AGMs.” [45]. 
3C2a3. Cross-reactivity (an antibody raised against one specific antigen has a competing high affinity 
toward a different antigen.) 
 The potential of cross-reactivity having adverse impact in a coronavirus environment is 
sufficiently serious to merit more detailed discussion in section 3C5. 
“our own findings that 21 out of 50 tissue antigens had moderate to strong reactions with the 
SARS-CoV-2 antibodies are a sufficiently strong indication of cross-reaction between SARS-CoV-2 
proteins and a variety of tissue antigens beyond just pulmonary tissue, which could lead to 
autoimmunity against connective tissue and the cardiovascular, gastrointestinal, and nervous systems.” 
[46]. 
Concern has been raised that using the full SARS-CoV-2 protein as a vaccine antigen (as is done 
for myriad vaccines) could lead to cross-reactivity-induced autoimmune disease.  “before considering a 
protein as a vaccine antigen, special care should be taken in analyzing the sequence of tissue cross-
reactive epitopes in order to avoid possible future side effects…..we feel that our own findings that 21 
out of 50 tissue antigens had moderate to strong reactions with the SARS-CoV-2 antibodies are a 
sufficiently strong indication of cross-reaction between SARS-CoV-2 proteins and a variety of tissue 
antigens beyond just pulmonary tissue, which could lead to autoimmunity against connective tissue and 
the cardiovascular, gastrointestinal, and nervous systems.”[47].  See section 3C5 for a more detailed 
discussion of the relation between molecular mimicry and autoimmune disease. 
3C2a4. Cross-Infection Enhancement (infection enhancement of one virus by antibodies from another 
virus) 
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 “anti-DENV antibodies can enhance the infectivity of DENV for certain classes of immune cells, 
causing increased viral production that correlates with severe disease outcomes. Similarly, ZIKV has 
been shown to undergo ADE in response to antibodies generated by other flaviviruses. We tested the 
neutralizing and enhancing potential of well-characterized broadly neutralizing human anti-DENV 
monoclonal antibodies (HMAbs) and human DENV immune sera against ZIKV using neutralization and 
ADE assays. We show that anti-DENV HMAbs, cross-react, do not neutralize, and greatly enhance ZIKV 
infection in vitro. DENV immune sera had varying degrees of neutralization against ZIKV and similarly 
enhanced ZIKV infection. Our results suggest that pre-existing DENV immunity may enhance ZIKV 
infection in vivo and may lead to increased disease severity. Understanding the interplay between ZIKV 
and DENV will be critical in informing public health responses and will be particularly valuable for ZIKV 
and DENV vaccine design and implementation” [48]. 
“Anti-Flavivirus antibodies are highly cross-reactive and may facilitate Zika virus (ZIKV) infection 
through the antibody-dependent enhancement (ADE) mechanism. We demonstrate that dengue-specific 
antibodies enhance the infection of a primary Brazilian ZIKV isolate in a Fc gamma RII-expressing K562 
cell line. In addition, we demonstrate that serum samples from dengue-immune pregnant women 
enhanced ZIKV infection. These findings highlight the need for epidemiological studies and animal 
models to further confirm the role of ADE in the development of congenital and neurological 
complications associated with ZIKV infections.” [49]. 
3C2b. Vaccine-Associated Virus Enhancement (where vaccinated individuals may be at increased risk for 
other respiratory viruses because they do not receive the non-specific immunity associated with natural 
infection) 
“Examining non-influenza viruses specifically, the odds of both coronavirus and human 
metapneumovirus in vaccinated individuals were significantly higher when compared to unvaccinated 
individuals (OR = 1.36 and 1.51, respectively) ... the laboratory data in our study showed increased odds 
of coronavirus and human metapneumovirus in individuals receiving influenza vaccination ... While 
influenza vaccination offers protection against influenza, natural influenza infection may reduce the risk 
of non-influenza respiratory viruses by providing temporary, non-specific immunity against these viruses 
... On the other hand, recently published studies have described the phenomenon of vaccine-associated 
virus interference; that is, vaccinated individuals may be at increased risk for other respiratory viruses 
because they do not receive the non-specific immunity associated with natural infection” [50]. 
“We identified a statistically significant increased risk of noninfluenza respiratory virus infection 
among TIV {trivalent inactivated influenza vaccine} recipients, including significant increases in the risk 
of rhinovirus and coxsackie/echovirus infection ... Receipt of TIV could increase influenza immunity at 
the expense of reduced immunity to noninfluenza respiratory viruses” [51]. 
“prior receipt of 2008-09 TIV was associated with increased risk of medically attended pH1N1 
illness during the spring-summer 2009, with estimated risk or odds ratios ranging from 1.4 to 2.5” [52]. 
“Among children there was an increase in the hazard of ARI {acute respiratory illness} caused by 
non-influenza respiratory pathogens post-influenza vaccination compared to unvaccinated children 
during the same period.” [53]. 
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“when influenza type A hit early, RSV {respiratory syncytial virus} outbreaks tended to be 
delayed, coronavirus outbreaks tended to be intensified” [54].  
“Here we show that reported influenza vaccination coverage rates for 29 OECD countries are 
associated significantly with recently observed SARS-CoV-2 infection rates in these countries. This early 
result, which merits further investigation, suggests that during the current coronavirus outbreak an 
influenza vaccination background might be a relevant factor for SARS-CoV-2 infection” [55].  
 
3C2c. Vaccine-Associated Imprinting Reduction (where vaccinations could also reduce the benefits of 
‘imprinting’, a protection conferred upon children who experienced infection at an early age) 
“Imprinting by the first childhood influenza infection is known to confer long-lasting immunity 
focused toward priming epitopes. Our findings suggest vaccine mismatch may negatively interact with 
imprinted immunity. The immunological mechanisms for imprint-regulated effect of vaccine (I-REV) 
warrant investigation.” [56]. 
“we suggest that the potential impact of distant influenza immune imprinting on current 
vaccination outcomes should be considered in the design of next generation or universal vaccine 
candidates” [57]. 
3C2d.  Non-Specific Vaccine Effects on Immune System (where previous infections can alter an 
individual's susceptibility to unrelated diseases) 
“vaccines against infectious diseases have nonspecific effects on the ability of the immune 
system to handle other pathogens. For instance, in randomized trials tuberculosis and measles vaccines 
are associated with a substantial reduction in overall child mortality, which cannot be explained by 
prevention of the target disease. New research suggests that the nonspecific effects of vaccines are 
related to cross-reactivity of the adaptive immune system with unrelated pathogens, and to training of 
the innate immune system through epigenetic reprogramming ... diphtheria-tetanus-pertussis (DTP) 
vaccine, although protective against the three target diseases, increases female mortality from other 
infectious diseases ... and it turned out that DTP vaccine administered after the measles vaccine was the 
explanation for the increased female mortality observed in the high-titer measles vaccine trials ...The 
effects of vaccines on the immune system may be modulated by other immune-modulating factors. 
Interactions are found between vaccines and high-dose vitamin A supplementation ... and two vaccines 
may have completely different effects when administered simultaneously ... We need to explore 
systematically what is likely to happen when our effective interventions are administered with other 
vaccines, drugs, or micronutrients and in different sequences.” [58]. 
“Epidemiological data suggest that previous infections can alter an individual's susceptibility to 
unrelated diseases … Substantial research efforts have expanded the classical concept of immune 
memory to also include long-lasting changes in innate immunity and antigen-independent reactivation 
of adaptive immunity. Collectively, these processes provide possible explanations on how acute 
infections might induce long-term changes that also affect immunity to unrelated diseases … This 
heightened state of alert enhances the ability of the immune system to combat even unrelated 
infections but may also increase susceptibility to autoimmunity. At the same time, infection-induced 
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changes in the regulatory compartment may dampen subsequent immune responses and promote 
pathogen persistence.” [59]. 
3C2e. Impact of Infection Route on Immune System (where immune protection can be influenced by the 
route of exposure/delivery) 
Vaccine-based infections have different routes of exposure from natural exposure, and this 
could lead to different impacts on the immune system. The typical vaccine is injected directly into the 
bloodstream, thereby bypassing much of the innate immune system, while the naturally acquired 
infection evolves through the time-consuming process of delay and resistance by the innate immune 
system.  Studies have been performed examining the effects of different routes of exposure.  For 
example: 
“our study demonstrates that the identification of candidate LAVs {live attenuated viruses} and 
immune protection markers in an animal model can be strongly affected by the route of infection used” 
[60]. 
“vaccine formulation and route of delivery can influence outcomes as suggested by our studies 
... Consideration of alternative methods rather than reliance on parenteral methods for vaccination can 
lead to vaccination strategies that produce improved efficacy and long-term memory response.” [61]. 
“we have compared pulmonary and subcutaneous delivery of BCG vaccine in the tuberculosis-
susceptible DBA/2 mouse strain, a model in which parenterally administered BCG vaccine does not 
protect against tuberculosis. Our data show that intranasally but not subcutaneously administered BCG 
confers robust protection against pulmonary tuberculosis challenge.” [62]. 
3C2f. Impact of Combinations of Toxic Stimuli (where people are exposed over their lifetime to myriad 
toxic stimuli that may impact the influence of any vaccine) 
“Toxic stimuli (stressors) exposure limits are typically based on single toxic stimuli experiments, 
but are presently used for both toxic stimuli in isolation and in combination with other toxic stimuli 
(simultaneous co-exposure or exposures separated in time). In the combination case, typically less of 
each constituent of the combination is required to cause damage compared to the amount determined 
from single stressor experiments.” [63].  Also, see [64]. 
“The effects of vaccines on the immune system may be modulated by other immune-modulating 
factors. Interactions are found between vaccines and high-dose vitamin A supplementation ... and two 
vaccines may have completely different effects when administered simultaneously ... We need to 
explore systematically what is likely to happen when our effective interventions are administered with 
other vaccines, drugs, or micronutrients and in different sequences.” [58]. 
3C2g.  Antigenic distance hypothesis (negative interference from prior season’s influenza vaccine (v1) on 
the current season’s vaccine (v2) protection may occur when the antigenic distance is small between v1 
and v2 (v1 ≈ v2) but large between v1 and the current epidemic (e) strain (v1 ≠ e).) 
“variation in repeat vaccine efficacy is due to differences in antigenic distances among vaccine 
strains and between the vaccine strains and the epidemic strain in each outbreak…..These results have 
implications for the selection of influenza vaccine strains, and also for vaccination strategies for other 
antigenically variable pathogens that might require repeated vaccination.” [65]. 
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“Prior vaccination effects varied significantly by season, consistent with the ADH. There was no 
interference by v1 in 2010-2011 when v1 v2 and v1 e, with comparable VE for v2 alone or v2 + v1: 34% 
(95% confidence interval [CI] = -51% to 71%) versus 34% (95% CI = -5% to 58%). Negative interference by 
v1 was suggested in 2012-2013 with nonsignificant reduction in VE when v1 v2 and v1 e: 49% (95% CI = -
47% to 83%) versus 28% (95% CI = -12% to 54%). Negative effects of prior vaccination were pronounced 
and statistically significant in 2014-2015 when v1 = v2 and v1 e: 65% (95% CI = 25% to 83%) versus -33% 
(95% CI = -78% to 1%)…..Effects of repeat influenza vaccination were consistent with the ADH and may 
have contributed to findings of low VE across recent A(H3N2) epidemics since 2010 in Canada.” [66]. 
“Studies in the 1970s and 1980s signaled concern that repeated influenza vaccination could 
affect vaccine protection. The antigenic distance hypothesis provided a theoretical framework to explain 
variability in repeat vaccination effects based on antigenic similarity between successive vaccine 
components and the epidemic strain…..A meta-analysis of vaccine effectiveness studies from 2010-11 
through 2014-15 shows substantial heterogeneity in repeat vaccination effects within and between 
seasons and subtypes. When negative effects were observed, they were most pronounced for H3N2, 
especially in 2014-15 when vaccine components were unchanged and antigenically distinct from the 
epidemic strain. Studies of repeated vaccination across multiple seasons suggest that vaccine 
effectiveness may be influenced by more than one prior season. In immunogenicity studies, repeated 
vaccination blunts the hemagglutinin antibody response, particularly for H3N2.” [67]. 
3C2h. Bystander activation (activation of T cells specific for an antigen X during an immune response 
against antigen Y) 
“In the last decade, reports have accumulated on various autoimmune disorders, such as 
idiopathic thrombocytopenia purpura, myopericarditis, primary ovarian failure, and systemic lupus 
erythematosus (SLE), following vaccination. In this review, we discuss the possible underlying 
mechanisms of autoimmune reactions following vaccinations and review cases of autoimmune diseases 
that have been correlated with vaccination. Molecular mimicry and bystander activation are reported as 
possible mechanisms by which vaccines can cause autoimmune reactions.” [68]. 
“Autoimmune reactions to vaccinations may rarely be induced in predisposed individuals by 
molecular mimicry or bystander activation mechanisms. Autoimmune reactions reliably considered 
vaccine-associated, include Guillain-Barre syndrome after 1976 swine influenza vaccine, immune 
thrombocytopenic purpura after measles/mumps/rubella vaccine, and myopericarditis after smallpox 
vaccination” [69]. 
“Three main mechanisms have been offered to explain the development of autoimmunity: 
molecular mimicry, epitope spreading, and bystander activation. The latter is characterized by auto-
reactive B and T cells that undergo activation in an antigen-independent manner, influencing the 
development and course of autoimmunity. Activation occurs due to a combination of an inflammatory 
milieu, co-signaling ligands, and interactions with neighboring cells. In this review, we will discuss the 
studies performed seeking to define the role of bystander activation in systemic and organ-specific 
ADs.” [70]. 
3C2i. Gut Microbiota (Impact of gut microbial composition on vaccine response) 
-Chemicals 
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“DEHP exposure altered bacterial communities both in composition and diversity, particularly 
decreases in Rothia sp. and Bifidobacterium longum in the DEHP group. Furthermore, DEHP exposure 
significantly enhanced anti-HBsAg-IgM responses in the DEHP group (p = 0.013). Early-life DEHP 
exposure alter gut microbiota of newborns and may change their immune responses in later life.” [71]. 
“Emerging evidence indicates a central role for the microbiome in immunity. However, causal 
evidence in humans is sparse…..However, in a second trial of subjects with low pre-existing antibody 
titers, there was significant impairment in H1N1-specific neutralization and binding IgG1 and IgA 
responses. In addition, in both studies antibiotics treatment resulted in (1) enhanced inflammatory 
signatures (including AP-1/NR4A expression), observed previously in the elderly, and increased dendritic 
cell activation; (2) divergent metabolic trajectories, with a 1,000-fold reduction in serum secondary bile 
acids, which was highly correlated with AP-1/NR4A signaling and inflammasome activation.” [72]. 
-Nutrition 
“In children living in low-income and middle-income countries, undernourishment and repetitive 
gastrointestinal infections are associated with the failure of oral vaccines. Intestinal dysbiosis associated 
with these environmental influences, as well as some host-related factors, compromises immune 
responses and negatively impacts vaccine efficacy.” [73].  
“Protein-deficient pigs vaccinated with oral AttHRV vaccine had lower protection rates against 
diarrhea post-VirHRV challenge and significantly increased fecal virus shedding titers (HIFM transplanted 
but not GF pigs) compared with their protein-sufficient counterparts. Reduced vaccine efficacy in 
protein-deficient pigs coincided with altered serum IFN-alpha, TNF-alpha, IL-12 and IFN-gamma 
responses to oral AttHRV vaccine and the suppression of multiple innate immune parameters and HRV-
specific IFN-gamma producing T cells post-challenge. In protein-deficient HIFM transplanted pigs, 
decreased serum KYN, but not TRP levels were observed throughout the experiment, suggesting an 
association between the altered TRP metabolism and immune responses…..our findings confirm the 
negative effects of protein deficiency, which were exacerbated in the HIFM transplanted pigs, on innate, 
T cell and cytokine immune responses to HRV and on vaccine efficacy, as well as on TRP-KYN 
metabolism.” [74]. 
“Oral vaccination efficacy has been found to vary considerably with differences in geographical 
locations and socioeconomic status. Specifically, in children living in resource-poor countries, 
undernourishment and chronic gastrointestinal (GI) infection are associated with the failure of 
OVs…..Both undernutrition and GI infection have been shown to profoundly affect the microbiota, 
inducing 'dysbiosis' characterized by narrowed bacterial diversity and increased frequency of bacterial 
clades associated with the induction of inflammation. Recent studies have demonstrated that the 
microbiota exerts a profound effect on the development of mucosal immune responses. Therefore, it 
seems likely that OV failure in resource-poor regions is affected by alterations to the immune response 
driven by dysbiotic changes to the microbiota.” [75]. 
3C2j. Homologous Challenge (the strain of challenge virus used in the testing assay is very closely related 
to the seed virus strain used to produce the vaccine that a subject received) Infection Enhancement 
“Cats were vaccinated with fixed autologous feline immunodeficiency virus (FIV)-infected cells in 
order to present viral proteins to the immune system of individual cats in an MHC-matched 
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fashion…..vaccinated cats were not protected. Instead, accelerated virus replication was found, an 
observation similar to what previous experiments using other vaccine candidates have shown. Here, the 
results of the present study are discussed in the light of enhancement of lentivirus infections as a 
complicating factor in lentivirus vaccine development.” [76]. 
“Immunogenicity and protective activity of four cell-based feline immunodeficiency virus (FIV) 
vaccines prepared with autologous lymphoblasts were investigated…..under one condition of testing, 
some vaccine sera enhanced FIV replication in vitro. As a further limit, the vaccines proved inefficient at 
priming animals for anamnestic immune responses. Two months after completion of primary 
immunization, the animals were challenged with a low dose of homologous ex vivo FIV. Collectively, 8 of 
20 vaccinees developed infection versus one of nine animals mock immunized with fixed uninfected 
autologous lymphoblasts. After a boosting and rechallenge with a higher virus dose, all remaining 
animals became infected, thus confirming their lack of protection.” [77]. 
“Immunization induced production of anti-CD134 and anti-SU antibodies that significantly 
inhibited FIV infection in vitro. However, no vaccine combination protected cats from FIV infection, and 
neat serum from vaccinated cats enhanced FIV growth in vitro. CD134+SU vaccinated cats exhibited 
increased CD4:CD8 ratio immediately prior to challenge, and antibodies were much more efficiently 
generated against vaccine by-products versus target antigens. Results suggest vaccination against viral 
and cryptic receptor epitopes yields neutralizing antibodies that synergistically inhibit FIV infection in 
vitro. Factors contributing to vaccine failure may include: (1) Heat-labile serum factors that enhance viral 
replication, (2) changes in circulating target cell populations induced by vaccination, and (3) weak 
immunogenicity of neutralizing epitopes compared to off-target vaccine components. Results reinforce 
the need to monitor vaccine preparation components and avoid non-specific immune stimulation during 
vaccination.” [78]. 
3C2k. Immune Evasion (evasion of host response to viral infection) 
“Influenza viruses have evolved numerous strategies in order to evade the host innate immune 
response…..The viral nonstructural (NS)1 protein acts at multiple levels to prevent IFN production: NS1 
can limit PAMP detection, block essential retinoic acid-inducible gene-I post-translational modifications 
and block the processing and export of IFN mRNAs…..NS1 may also limit IFN responses by preventing 
expression of antiviral proteins or by directly inhibiting their activities…..Other strategies used by 
influenza viruses to evade the effects of IFN include: limiting PAMP formation, general inhibition of host 
cell protein synthesis, replication compartment, replication speed, induction/inhibition of apoptosis and 
reduced sensitivity to host antiviral proteins.” [79]. 
“Strategies of immune evasion and modulation used by PRRSV affect both innate and adaptive 
immune responses. In infected cells, PRRSV sequesters itself to limit PRRs detection, suppresses type I 
IFN production and signaling, manipulates the cytokine responses and modulates apoptosis. PRRSV 
structural protein (N) and nonstructional proteins (nsp1, nsp2, nsp4 and nsp11) play significant roles in 
attenuating signaling through the IFN induction and JAK/STAT pathway. In addition, PRRSV evolves 
mechanisms to inhibit the process of antigen presentation and induce proliferation and activation of 
Tregs, causing deficiency of subsequent adaptive immune responses. The effect of ADE also facilitates 
the entry and propagation of PRRSV.” [80]. 
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“This selection pressure exerted by complement on viruses has made them evolve a multitude 
of countermeasures. These include targeting the recognition molecules for the avoidance of detection, 
targeting key enzymes and complexes of the complement pathways like C3 convertases and C5b-9 
formation - either by encoding complement regulators or by recruiting membrane-bound and soluble 
host complement regulators, cleaving complement proteins by encoding protease, and inhibiting the 
synthesis of complement proteins. Additionally, viruses also exploit the complement system for their 
own benefit. For example, they use complement receptors as well as membrane regulators for cellular 
entry as well as their spread.” [81]. 
“the major mechanisms of immune evasion strategies of MERS‐CoV. We have demonstrated 
that M, 4a, 4b proteins and Plppro of MERS‐CoV inhibit the type I interferon (IFN) and nuclear factor‐κB 
signaling pathways and therefore facilitate innate immune evasion.  In addition, nonstructural protein 
4a (NSP4a), NSP4b, and NSP15 inhibit doublestranded RNA sensors. Therefore, the mentioned proteins 
limit early induction of IFN and cause rapid apoptosis of macrophages. MERS‐CoV strongly inhibits the 
activation of T cells with downregulation of antigen presentation. In addition, uncontrolled secretion of 
interferon ɣ‐induced protein 10 and monocyte chemoattractant protein‐1 can suppress proliferation of 
human myeloid progenitor cells.” [82]. 
3C2l. Immune Interference (interference from circulating antibody to the vaccine virus) 
“immune interference during co-inoculation was examined using DNA vaccines expressing 
lentiviral Envs and Gag from gene sequences optimized for efficient expression in mammalian cells 
(codon-optimized). BALB/c mice vaccinated in separate hind legs with each plasmid individually elicited 
high titer immune responses, however, when HIV-1 Env(gp120) and HIV-1 Gag(p55) DNA plasmids were 
co-inoculated, there was a reduction in the immune responses elicited to HIV-1 Gag(p55)…..Therefore, 
anti-HIV-1 Gag immune interference appears specific to co-immunizations with HIV-1 Env(gp120) and 
may involve a yet undefined immunological mechanism(s).” [83]. 
“We compared the effect of order of administration of investigational alphavirus vaccines on 
neutralizing antibody response. Volunteers who received the inactivated eastern and western equine 
encephalitis (EEE and WEE) vaccines before live attenuated Venezuelan (VEE) vaccine had significantly 
lower rates of antibody response than those receiving VEE vaccine before EEE and WEE vaccines (66.7% 
vs. 80.6%; p=0.026). The odds of having a VEE antibody non-response among those initially receiving EEE 
and WEE vaccines, adjusted for gender, were significant (odds ratio [OR]=2.20; 95% CI=1.2-4.1 
[p=0.0145]) as were the odds of non-response among females adjusted for group (OR=1.81; 95% CI=1.2-
2.7 [p=0.0037]). Antibody interference and gender effect have major implications for vaccine strategy 
among those receiving multiple alphavirus vaccines and those developing next generation vaccines for 
these threats.” [84]. 
3C2l1.  Original antigenic sin (propensity of the body's immune system to preferentially utilize 
immunological memory based on a previous infection when a second slightly different version of that 
foreign entity (e.g. a virus or bacterium) is encountered.) 
“Since all flaviviruses are antigenically related, they are prone to phenomena of immunological 
memory ('original antigenic sin'), which can modulate immune responses in the course of sequential 
infections and/or vaccinations. In our study, we analyzed the influence of pre-existing YF vaccine-derived 
immunity on the antibody response to TBE vaccination. By comparing samples from YF pre-vaccinated 
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and flavivirus-naive individuals, we show that YF immunity not only caused a significant impairment of 
the neutralizing antibody response to TBE vaccination but also a reduction of the specific TBE virus 
neutralizing activities (NT/ELISA-titer ratios). Our results point to a possible negative effect of pre-
existing cross-reactive immunity on the outcome of flavivirus vaccination that may also pertain to other 
combinations of sequential flavivirus infections and/or vaccinations.” [85]. 
“We found that single-clade A, B and C vaccines applied alone induced only limited cross-clade 
reactivity and that the epitope hierarchy varied according to the immunizing clade. However, combining 
single-clade HIV-1 vaccines into multi-clade formulations resulted in multiple forms of in vivo immune 
interference such as original antigenic sin and antagonism, which dampened or even abrogated 
induction of responses to epitope variants and reduced the breadth of induced T cell responses. 
Simultaneous administration of individual clade-specific vaccines into anatomically separated sites on 
the body alleviated antagonism and increased the number of detectable epitope responses.” [86]. 
“it seems clear that OAS can also be detrimental when the boosting of memory responses to 
conserved, but nonprotective, epitopes comes at the expense of generating new responses against 
protective, but antigenically drifted, epitopes.” [87]. 
“Antigenic sin has been demonstrated to occur in several infectious diseases in both animals and 
humans, including human influenza infection and dengue fever…..In the context of viral infections, it is 
expected that if we are exposed to a native strain of a pathogen, we should be able to mount a 
secondary immune response on subsequent exposure to the same pathogen. "Original antigenic sin" will 
not contradict this well-established immunological process, as long as the subsequent infectious antigen 
is identical to the original one. But "original antigenic sin" implies that when the epitope varies slightly, 
then the immune system relies on memory of the earlier infection, rather than mount another primary 
or secondary response to the new epitope which would allow faster and stronger responses. The result 
is that the immunological response may be inadequate against the new strain, because the immune 
system does not adapt and instead relies on its memory to mount a response. In the case of vaccines, if 
we only immunize to a single strain or epitope, and if that strain/epitope changes over time, then the 
immune system is unable to mount an accurate secondary response. In addition, depending of the first 
viral exposure the secondary immune response can result in an antibody-dependent enhancement of 
the disease or at the opposite, it could induce anergy. Both of them triggering loss of pathogen control 
and inducing aberrant clinical consequences.” [88]. 
3C2m. Prior Influenza Infection (effects of prior influenza infection on severity of future disease 
symptoms) 
“Seventy patients met selection criteria. Mean age was 66 years. Sixty-four (91%) patients had 
at least one underlying co-morbid condition; these conditions included COPD, congestive heart failure, 
diabetes, and cancer. 60/70 (85%) tested positive for Influenza A, and 43 tested positive for H1N1. 
Oseltamivir was initiated in 55 (78%) patients. Forty-four percent of the patients had been vaccinated. 
When separated by vaccination status, those who had been vaccinated had higher rates of ICU 
admission, need for mechanical or non-invasive ventilation, and mortality. All but mortality reached 
statistical significance…..The data suggest that there was no protective effect from prior vaccination in 
preventing hospital admission, respiratory failure, and mortality in this population of older men 
admitted to the hospital with influenza.” [89]. 
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“mice were first primed by either infection or immunization with A/Puerto Rico/8/34 (PR8) 
virus, then immunized with whole-inactivated A/Fort Monmouth/1/47 (FM1) virus. The ensuing vaccine 
responses and the protective efficacy of FM1 were superior in PR8 infection-primed mice compared to 
PR8 immunization-primed or unprimed mice. Increased FM1-specific Ab responses of PR8 infection-
primed mice also broadened cross-reactivity against contemporary as well as antigenically more drifted 
strains. Further, prior infection heightened the protective efficacy of antigenically distant strains, such as 
A/Brisbane/59/2006 infection followed by immunization with split pandemic H1N1 vaccine 
(A/California/07/2009). Therefore, influenza infection is a significant priming event that intensifies 
future vaccine responses against drift strains.” [90]. 
“During the three influenza seasons, 5838 ILI [influenza-like illness] episodes (4127 subjects) 
were analysed. Subjects who had an episode of MA-fluA [medically attended influenza A] in the prior 
season were at a significantly lower risk of MA-fluA in the current season (adjusted odds ratio: 0.38, 95% 
CI: 0.30-0.50). The overall adjusted VE was 28% (95% CI, 14-40). VE was substantially lower in subjects 
vaccinated in the prior season compared to those who had not been vaccinated in prior season (19%; 
95% CI: 0-35 vs 46%; 95% CI: 26-60, test for interaction, P value <0.05). In subjects who did not have MA-
fluA in the prior season showed the attenuation of VE due to repeated vaccination (13%; 95% CI: -7 to 
30 vs 44%; 95% CI: 24-59, test for interaction, P < 0.05). However this effect was not detected in subjects 
who had contracted MA-fluA in the prior season…..Negative effects of repeated vaccination were 
significant among those without history of MA-fluA in the prior season.” [91]. 
“Reduced seasonal influenza vaccine effectiveness (VE) was observed in individuals who 
received repeated annual vaccinations. Preexisting influenza antibody levels were also found inversely 
correlated with postvaccination titers. These reports suggest that preexisting immunity may affect 
contemporary seasonal vaccine performance.” [92]. 
“Current- and previous-season vaccination generated similar levels of protection, and vaccine-
induced protection was greatest for individuals not vaccinated during the prior 5 years.” [93]. 
“Participants who reported receipt of vaccination during either of the previous 2 years had a 
lower mean fold rise against all strains than with those who did not. Mean fold rises for A(H3N2) and 
B/Yamagata were particularly weak after repeated vaccination with the same vaccine strain, but we did 
not generally find significant differences in the proportions of participants with postvaccination titers >= 
40 and >= 160…..Overall, we found that reduced antibody responses in repeat vaccinees were 
particularly reduced among older adults who had received vaccination against the same strains in 
preceding years.” [94]. 
“long-term effects on mortality have never been supported by direct evidence. In this study we 
assessed the long-term outcome of influenza vaccination on mortality in the elderly by conducting a 25-
year follow-up study of a RCT on the efficacy of influenza vaccination as baseline…..outcomes included 
all-cause mortality, influenza-related mortality and seasonal mortality…..Single influenza vaccination did 
not reduce all-cause mortality when compared to placebo ( adjusted HR 0.95, 95% CI 0.85-1.05). Also, no 
differences between vaccination and placebo group were shown for underlying causes of death or 
seasonal mortality…..In conclusion, this study did not demonstrate a statistically significant effect 
following single influenza vaccination on long-term mortality in community-dwelling elderly in general.” 
[95].  
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“Influenza was identified in 78 (24%) households and 125 (9%) individuals; the infection risk was 
8.5% in the vaccinated and 8.9% in the unvaccinated (P = .83). Adjusted vaccine effectiveness in 
preventing community-acquired influenza was 31% (95% confidence interval [CI], -7% to 55%). In 
vaccinated subjects with no evidence of prior season vaccination, significant protection (62% [95% CI, 
17%-82%]) against community-acquired influenza was demonstrated. Substantially lower effectiveness 
was noted among subjects who were vaccinated in both the current and prior season. There was no 
evidence that vaccination prevented household transmission once influenza was introduced; adults 
were at particular risk despite vaccination…..Vaccine effectiveness estimates were lower than those 
demonstrated in other observational studies carried out during the same season. The unexpected 
findings of lower effectiveness with repeated vaccination and no protection given household exposure 
require further study.” [96]. 
3C2n. Timing between Viral Exposures (elapsed time between viral exposures) 
“Comprehending the mechanisms behind the impact of vaccine regimens on immunity is critical 
for improving vaccines. Indeed, the time-interval between immunizations may influence B and T cells, as 
well as innate responses. We compared two vaccine schedules using cynomolgus macaques immunized 
with an attenuated vaccinia virus. Two subcutaneous injections 2 weeks apart led to an impaired 
secondary antibody response and similar innate myeloid responses to both immunizations. In contrast, a 
delayed boost (2 months) improved the quality of the antibody response and involved more 
activated/mature innate cells, induced late after the prime and responding to the recall. The magnitude 
and quality of the secondary antibody response correlated with the abundance of these neutrophils, 
monocytes, and dendritic cells that were modified phenotypically and enriched prior to revaccination at 
2 months, but not 2 weeks. These late phenotypic modifications were associated with an enhanced ex 
vivo cytokine production (including IL-12/23 and IL-1beta) by PBMCs short after the second 
immunization, linking phenotype and functions. This integrated analysis reveals a deep impact of the 
timing between immunizations, and highlights the importance of early but also late innate responses 
involving phenotypical changes, in shaping humoral immunity.” [97]. 
“This study evaluates the influenza vaccine effectiveness (VE) in preventing laboratory-
confirmed cases in Navarre, Spain, in the 2011/12 season in which the peak was delayed until week 7 of 
2012…..These results suggest a low preventive effect of the 2011/12 seasonal influenza vaccine, and a 
decline in VE with time since vaccination.” [98]. 
“During 3 influenza seasons, 1668 influenza-like illness episodes were analyzed, including 421 
and 358 episodes of MA-fluA and MA-fluB, respectively.…..Repeated previous vaccinations over multiple 
seasons had significant dose-dependent negative impacts on VE against both MA-fluA and MA-fluB.” 
[99]. 
“Six studies assessed efficacy against MAI in children, yielding the risk ratios (RR) of 2.04 (95% CI 
1.29-3.22) when circulating strains mismatched vaccine strains, and 0.64 (0.33-1.22) when circulating 
strains matched vaccine strains. When stratified by vaccine types, the reduced efficacy was significant 
for live attenuated influenza vaccine only…..Influenza vaccine efficacy against mismatch strains was 
lower in repeatedly vaccinated children as compared with those vaccinated for the current season only.” 
[100]. 
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3C2o. Vaccine associated enhanced respiratory disease (where vaccination enhances respiratory 
disease) 
“Vaccine-induced disease enhancement has been described in connection with several viral 
vaccines in animal models and in humans. We investigated a swine model to evaluate mismatched 
influenza vaccine-associated enhanced respiratory disease (VAERD) after pH1N1 infection. Vaccinating 
pigs with whole inactivated H1N2 (human-like) virus vaccine (WIV-H1N2) resulted in enhanced 
pneumonia and disease after pH1N1 infection…..These cross-reactive anti-HA2 antibodies enhanced 
pH1N1 infection of Madin-Darby canine kidney cells by promoting virus membrane fusion activity. The 
enhanced fusion activity correlated with lung pathology in pigs.” [101]. 
“Vaccine-associated enhanced respiratory disease (VAERD) can occur when pigs are challenged 
with heterologous virus in the presence of non-neutralizing but cross-reactive antibodies elicited by 
whole inactivated virus (WIV) vaccine. The aim of this study was to compare the effects of heterologous 
delta1-H1N2 influenza A virus (IAV) challenge of pigs after vaccination with 2009 pandemic H1N1 virus 
(H1N1pdm09) recombinant hemagglutinin (HA) subunit vaccine (HA-SV) or temperature-sensitive live 
attenuated influenza virus (LAIV) vaccine, and to assess the role of immunity to HA in the development 
of VAERD. Both HA-SV and LAIV vaccines induced high neutralizing antibodies to virus with homologous 
HA (H1N1pdm09), but not heterologous challenge virus (delta1-H1N2). LAIV partially protected pigs, 
resulting in reduced virus shedding and faster viral clearance, as no virus was detected in the lungs by 5 
days post infection (dpi). HA-SV vaccinated pigs developed more severe lung and tracheal lesions 
consistent with VAERD following challenge. These results demonstrate that the immune response 
against the HA protein alone is sufficient to cause VAERD following heterologous challenge.” [102]. 
“Control of influenza A virus (IAV) in pigs is done by vaccination of females to provide 
maternally-derived antibodies (MDA) through colostrum. Our aim was to evaluate if MDA interfere with 
IAV infection, clinical disease, and transmission in non-vaccinated piglets. In the first study, naive sows 
were vaccinated with H1N2-delta1 whole inactivated virus (WIV) vaccine. In a follow-up study 
seropositive sows to 2009 pandemic H1N1 (H1N1pdm09) were boosted with H1N1pdm09 WIV or 
secondary experimental infection (EXP). MDA-positive pigs were challenged with homologous or 
heterologous virus, and MDA-negative control groups were included. WIV-MDA piglets were protected 
from homologous infection. However, piglets with WIV-derived MDA subsequently challenged with 
heterologous virus developed vaccine associated enhanced respiratory disease (VAERD), regardless of 
history of natural exposure in the sows. Our data indicates that although high titers of vaccine-derived 
MDA reduced homologous virus infection, transmission, and disease, MDA alone was sufficient to 
induce VAERD upon heterologous infection.” [103]. 
3C2p. Chronic Immune Activation 
“Dr. Sharilyn Stanley and colleagues inoculated 13 asymptomatic HIV-infected people and 10 
uninfected volunteers with tetanus booster shots to stimulate their immune system. Blood samples 
were drawn on the day of the injection and 3, 7, 14, 21, 28, and 42 days later. Findings showed that the 
amount of HIV in the blood streams of HIV-infected subjects increased 2- to 36-fold following 
immunization. Notably, the virus was much more readily grown from the blood cells of 9 of the HIV-
infected patients after immunization. In addition, examinations of the immune system cells of the 
uninfected volunteers found that cells from 7 of these 10 people were more easily infected with HIV in 
the test tube after immunization than before immunization. Overall, data suggest that ongoing immune 
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activation may play a part in HIV pathogenesis and may also enhance susceptibility of uninfected people 
to HIV.” [104]. 
“HIV co-infection is the most critical risk factor for the reactivation of latent tuberculosis (TB) 
infection (LTBI). While CD4(+) T cell depletion has been considered the major cause of HIV-induced 
reactivation of LTBI, recent work in macaques co-infected with Mycobacterium tuberculosis 
(Mtb)/simian immunodeficiency virus (SIV) suggests that cytopathic effects of SIV resulting in chronic 
immune activation and dysregulation of T cell homeostasis correlate with reactivation of LTBI. This 
review builds on compelling data that the reactivation of LTBI during HIV co-infection is likely to be 
driven by the events of HIV replication and therefore highlights the need to have optimum translational 
interventions directed at reactivation due to co-infection.” [105]. 
“Systemic chronic immune activation is considered today as the driving force of CD4+ T-cell 
depletion and acquired immunodeficiency syndrome (AIDS). A residual chronic immune activation 
persists even in HIV-infected patients in which viral replication is successfully inhibited by anti-retroviral 
therapy, with the extent of this residual immune activation being associated with CD4+ T-cell loss.” 
[106]. 
3C3.  Potential Short- and Long-Term Diseases Resulting from Vaccines 
3C3a.  Tracking Deficiencies for Vaccine Adverse Effects 
While the efficacy issues for a COVID-19 vaccine have been enumerated extensively in recent 
reviews [29, 34], more emphasis needs to be placed on ensuring mid- and long-term safety are 
achieved.  Vaccines do not appear to have the same safety requirements as many drugs.  For example, 
consider the following excerpts from selected vaccine inserts relative to safety [107]: 
-MMR Vaccine “M-M-R II has not been evaluated for carcinogenic or mutagenic potential, or potential to 
impair fertility ... Animal reproduction studies have not been conducted with M-M-R II.”; 
-Influenza Vaccine “FLUARIX QUADRIVALENT has not been evaluated for carcinogenic or mutagenic 
potential or male infertility in animals.”; 
-DTAP Vaccine “INFANRIX has not been evaluated for carcinogenic or mutagenic potential or for 
impairment of fertility.”; and 
-HPV Vaccine “GARDASIL 9 has not been evaluated for the potential to cause carcinogenicity, 
genotoxicity or impairment of male fertility.” 
Long-term safety studies of vaccines are rare.  The typical vaccine study is aimed at efficacy.  
Such studies tend to be a few months long, and the main evaluation criterion is titers of antibody in the 
serum. 
Vaccines, especially childhood vaccines, are administered according to a schedule, which now 
comprises about seventy+ doses covering about sixteen vaccines.  The schedule-based combination 
effects of these seventy+ vaccine doses have not been tested, and, therefore, adverse effects due to 
real-life vaccine synergies are unknown.  Such vaccine combination experiments cannot be limited to 
the pristine environment of the laboratory, but require testing in humans who are exposed to myriad 
toxic stimuli that could impact vaccine combination synergies. 
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Much of the published data for vaccine adverse events (at least in the USA) originates from the 
Vaccine Adverse Event Reporting System (VAERS) database.  VAERS is a passive monitoring system, and, 
like all similar systems, suffers from substantial under-reporting of adverse events [108].  A 
groundbreaking study [109], performed by Harvard Pilgrim Healthcare, Inc, reported that “fewer than 
1% of vaccine adverse events are reported”.  In other words, the actual numbers of adverse reactions to 
vaccines are one to two orders of magnitude higher than those reported in VAERS! 
The methodology used by Harvard Pilgrim Healthcare. Inc, for obtaining this result was as 
follows: “Every patient receiving a vaccine was automatically identified, and for the next 30 days, their 
health care diagnostic codes, laboratory tests, and medication prescriptions are evaluated for values 
suggestive of an adverse vaccine event. When a possible adverse event was detected, it was recorded, 
and the appropriate clinician was to be notified electronically.” 
Thus, these adverse events that were identified are single-visit short-term adverse events 
(within thirty days of the vaccination).  They do not reflect the results of vaccination combinations 
administered over a longer period than thirty days, and they do not reflect results of vaccinations of any 
type in the mid-or long-term [109]. 
If fewer than 1% of vaccine adverse events are reported, how well does this sample reflect the 
total number of adverse events actually experienced?  This is not a randomly-selected sample, as would 
be required for a statistically-valid result.  Thus, even analyses of short-term adverse effects based on 
VAERS data are severely flawed.  And, if fewer than 1% of these short-term adverse events are reported, 
what fraction of longer-term adverse events (where the connection between the adverse event and the 
vaccination becomes more tenuous as time proceeds) would be reported?  One can only conclude that a 
negligible fraction of long-term adverse events is reported in a passive monitoring system like VAERS. 
3C3b. Diseases Triggered by Vaccines 
A brief analysis was performed of the vaccine biomedical literature to identify diseases 
potentially triggered by vaccination, especially in the long-term.  It should be noted the biomedical 
literature is very sparse with studies on long-term vaccine effects, especially long-term adverse effects.  
Large numbers of people and long periods of time are required to identify such adverse events, and 
draw statistically-valid connections between vaccinations and disease.  These efforts would be very 
resource-intensive, and there appears to be little motivation among the vaccine producers and 
regulators to make these resources available for such studies.  Thus, the following examples reflect the 
extremely small tip of an extremely large iceberg of long-term adverse vaccine effects.  
The two main categories of diseases reported in the biomedical literature triggered by 
vaccinations are Autoimmune (e.g., Systemic Lupus Erythematosus, Psoriasis, Arthritis, Multiple 
Sclerosis, Hepatitis, Uveitis, Pseudolymphoma, Guillain-Barre Syndrome, Thrombocytopenic Purpura, 
etc.) and Neurological (e.g., Autism, Central Demyelinating Diseases, Developmental Disability, Febrile 
seizures, Narcolepsy,  Encephalomyelitis, Autonomic Dysfunction, etc.).  Others include Diabetes, 
Gastrointestinal, Joint-related, Necrobiotic Granuloma, Neutropenia, Pulmonary Fibrosis, etc.   
A few specific examples are presented in the following, and a larger bibliography of vaccine 
adverse effects is presented in Appendix 1. 
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“Main syndromes associated with systemic toxicity of adjuvanted vaccines…..Acute phase 
response (APR). . . . .Hypersensitivity reactions. . . . .Induction or worsening of autoimmune diseases. . . . 
. Modification of drug hepatic metabolism . . . . .Vascular leak syndrome (VLS) . . . . .  Oral 
immunosuppression or tolerance post vaccination.” [110]. 
“vaccinations may also contribute to the mosaic of autoimmunity. Evidence for the association 
of vaccinations and the development of these diseases is presented in this review. Infrequently reported 
post-vaccination autoimmune diseases include systemic lupus erythematosus, rheumatoid arthritis, 
inflammatory myopathies, multiple sclerosis, Guillain-Barre syndrome, and vasculitis.” [111]. 
“Toplak et al…..reported the production of autoantibodies (such as antinuclear and 
antiphospholipid antibodies) in 92 healthy medical workers up to 6 months after influenza vaccination.  
Other studies have demonstrated a latency period of years between HiB vaccination and diabetes 
mellitus, and between HBV vaccination and demyelinating events…..In conclusion, latency periods can 
range from days to years for postinfection and postvaccination autoimmunity.” [112]. 
“Adults receiving HBV had significantly increased odds ratios (OR) for multiple sclerosis (OR = 
5.2, p < 0.0003, 95% Confidence Interval (CI) = 1.9 - 20), optic neuritis (OR = 14, p < 0.0002, 95% CI = 2.3 - 
560), vasculitis (OR = 2.6, p < 0.04, 95% CI = 1.03 - 8.7), arthritis (OR = 2.01, p < 0.0003, 95% CI = 1.3 - 
3.1), alopecia (OR = 7.2, p < 0.0001, 95% CI = 3.2 - 20), lupus erythematosus (OR = 9.1, p < 0.0001, 95% CI 
= 2.3 - 76), rheumatoid arthritis (OR = 18, p < 0.0001, 95% CI = 3.1 - 740), and thrombocytopenia (OR = 
2.3, p < 0.04, 95% CI = 1.02 - 6.2) in comparison to the TCV group. Minimal confounding or systematic 
error was observed.” [113]. 
“The difference in cumulative incidence between those receiving 4 doses and those receiving 0 
doses is 54 cases of IDDM/100,000 ( P =0.026) at 7 years, (relative risk=1.26 ). Most of the extra cases of 
IDDM appeared in statistically significant clusters that occurred in periods starting approximately 38 
months after immunization and lasting approximately 6-8 months. Immunization with pediatric vaccines 
increased the risk of insulin diabetes in NOD mice…..Exposure to HiB immunization is associated with an 
increased risk of IDDM. NOD mice can be used as an animal model of vaccine induced diabetes.” [114]. 
3C4. Time Required for Credible COVID-19 Vaccine Safety Studies 
As the above results have shown, vaccines can have long-term impacts on the immune system 
(positive and negative), and short and long-term effects on other diseases.  The effects of vaccines can 
vary according to route of infection, prior history of vaccinations, and, as stated by Benn et al above, 
administration “with other vaccines, drugs, or micronutrients and in different sequences.” [58].  To 
accelerate the time required to demonstrate long-term safety, laboratory experiments are usually done 
using animals with relatively short lifespans whose responses to myriad toxic stimuli are similar to that 
of human beings. 
One major difference between these animal experiments and the human model is that the 
laboratory experiments are usually performed with the administration of a single toxic stimulant, or 
maybe two, while the human model lives in a sea of toxic stimuli.  Also, it is not always clear which 
animal model simulates the human model best for response to vaccination.   
There are many examples in the biomedical literature where combined exposures to toxic 
stimuli showed adverse effects whereas exposures to the same stimuli in isolation (at the same dosages) 
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showed no adverse effects [63-64].  Thus, unless these laboratory experiments are performed with a 
range of combinations of associated immunomodulators, they would not be credible for safety 
assessment purposes.  Such experiments would require enormous amounts of financial and time 
resources. 
The other alternative is to perform these safety studies with human beings.  For long-term 
safety studies (e.g., potential vaccine effects on initiating cancer or Alzheimer’s Disease), decades could 
be required for credible results.  Thus, there is a major disconnect between the time required for 
credible safety studies of a COVID-19 vaccine and the one-year or less vaccine commercialization being 
propounded by decision-makers and the media today. 
3C5. Molecular mimicry and the invalid genetic basis of vaccine pre-clinical tests: the new 
vaccinology scenario for designing safe and effective vaccines.  
 The above analyzed Covid-19 vaccine safety considerations become even more cogent in light 
of the fact that cross-reactivity might represent the mechanism underlying the immunopathology and 
the disease multitude associated with the coronavirus infection [115]. The rationale is that the sharing 
of peptides between SARS-CoV-2 and human proteins might trigger immune responses hitting not only 
the virus but also the human proteins, with consequent autoimmune pathologies in the human host 
[116]. Hence, the massive viral vs. human peptide commonalities described since 2000 [117-118] clearly 
explain how the protective anti-viral antibody immune response can become a pathogenic autoimmune 
attack against the human organism, thereby addressing the issue of why SARS-CoV-2 so heavily attacks 
the respiratory system [119]. The scientific cross-reactivity context and the clinical data showing that 
immunization with SARS-CoV antigens causes severe pneumonia [120] suggest a prominent pathogenic 
role of anti-SARS-CoV antibodies in Covid. In fact, emerging reports show that severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) infection precedes the appearance of various autoimmune and 
autoinflammatory diseases, including paediatric inflammatory multisystemic syndrome or multisystem 
inflammatory syndrome in children [121-122]. Simply put, the current race for obtaining a highly 
immunogenic anti-SARS-CoV-2 vaccine might actually equate to a race for producing a highly lethal 
vaccine also in light of the fact that adjuvanted anti-SARS-CoV-2 would have a higher immunogenicity 
and autoimmune pathogenicity when compared to SARS-CoV-2 infection. 
This risk of cross-reactivity further increases when considering that it cannot be estimated with 
the current vaccine pre-clinical tests [123-124]. Indeed, the level of peptide sharing is highest between 
pathogens and human, murine, and rat proteomes, while is minimal (or absent) with proteomes from 
nonhuman primates such as gorilla, chimpanzee, and rhesus macaque. That is, from the genetic point of 
view, primates are unreliable animal models for revealing potential autoimmune cross-reactions in 
preclinical testing of immunotherapies since, obviously, no cross-reactions can occur in primates in 
absentia of shared sequences. 
On the whole, the above-exposed data open new scenarios in vaccinology by confirming the 
basic concept first stated in 2000 [117] and then repeatedly illustrated [125-128], according to which 
only peptide sequences  derived from pathogens and absent in the human proteome, i.e., ‘non-self’ 
peptides’, can lead to safe and efficacious immunotherapies. 
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